Arta Finance Wealth Management LLC Makes New $626,000 Investment in Dr. Reddy’s Laboratories Ltd $RDY

Arta Finance Wealth Management LLC bought a new position in Dr. Reddy’s Laboratories Ltd (NYSE:RDY) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 44,581 shares of the company’s stock, valued at approximately $626,000.

A number of other hedge funds also recently made changes to their positions in the stock. Robeco Institutional Asset Management B.V. increased its position in Dr. Reddy’s Laboratories by 7.6% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 13,084,506 shares of the company’s stock worth $182,921,000 after purchasing an additional 921,078 shares in the last quarter. Aikya Investment Management Ltd lifted its stake in shares of Dr. Reddy’s Laboratories by 5.7% in the 3rd quarter. Aikya Investment Management Ltd now owns 6,715,007 shares of the company’s stock valued at $93,876,000 after acquiring an additional 360,028 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Dr. Reddy’s Laboratories by 2.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 6,027,710 shares of the company’s stock valued at $84,267,000 after acquiring an additional 116,924 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Dr. Reddy’s Laboratories by 3.0% during the 3rd quarter. Vanguard Group Inc. now owns 5,123,709 shares of the company’s stock valued at $71,629,000 after acquiring an additional 148,662 shares in the last quarter. Finally, Bessemer Group Inc. grew its position in Dr. Reddy’s Laboratories by 30.9% during the 3rd quarter. Bessemer Group Inc. now owns 1,350,988 shares of the company’s stock worth $18,887,000 after acquiring an additional 318,621 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Dr. Reddy’s Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, February 13th. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $16.90.

Dr. Reddy’s Laboratories Price Performance

RDY stock opened at $13.34 on Friday. The company has a fifty day moving average price of $14.04 and a 200-day moving average price of $13.99. The company has a market capitalization of $11.14 billion, a P/E ratio of 17.33, a PEG ratio of 13.18 and a beta of 0.35. Dr. Reddy’s Laboratories Ltd has a 52-week low of $12.26 and a 52-week high of $16.17. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.38 and a current ratio of 1.88.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings data on Wednesday, January 21st. The company reported $0.16 earnings per share for the quarter, hitting the consensus estimate of $0.16. The company had revenue of $969.81 million for the quarter, compared to analysts’ expectations of $963.84 million. Dr. Reddy’s Laboratories had a net margin of 16.41% and a return on equity of 15.89%. As a group, equities analysts expect that Dr. Reddy’s Laboratories Ltd will post 0.8 EPS for the current year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.